Differentiation and function of intratumoral memory-phenotype CD8+ T cells
瘤内记忆表型 CD8 T 细胞的分化和功能
基本信息
- 批准号:10402376
- 负责人:
- 金额:$ 40.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-17 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AdultAntigensAreaAtypical lymphocyteAutoantigensAutomobile DrivingBiological AssayBiologyCD8-Positive T-LymphocytesCD8B1 geneCancer ModelCancer PatientCell Differentiation processCellsCuesDataDendritic CellsDevelopmentDifferentiation AntigensExhibitsFOXP3 geneGene Expression ProfilingGoalsHumanImmuneImmune responseImmunologicsIndividualInfiltrationInflammatoryInterferon Type IIKnowledgeLaboratoriesLigandsMalignant NeoplasmsMalignant neoplasm of prostateMarker DiscoveryMemoryMinorMolecularMusMutateNatureOncogenesPeptidesPhasePhenotypePlayPopulationProcessProductionPropertyProstatic NeoplasmsRecurrenceRegulatory T-LymphocyteReproducibilityResearchRoleSignal TransductionSpecificitySuggestionT memory cellT-LymphocyteT-Lymphocyte SubsetsT-cell receptor repertoireTestingThymus GlandTransplantationTumor AntigensTumor ImmunityTumor stageTumor-Infiltrating LymphocytesTumor-infiltrating immune cellsUp-RegulationWorkanti-PD-1basecancer cellcancer immunotherapycancer typecomparativedensityexperienceexperimental studyhuman diseaseimmune checkpoint blockadeinsightinterestmelanomamouse modelnovelnovel markerpathogenprogrammed cell death protein 1receptorresponsesuccessthymocytetranscription factortransgenic adenocarcinoma of mouse prostatetumor
项目摘要
ABSTRACT
While considerable evidence demonstrates that CD8+ TILs reactive to mutated or non-mutated tumor antigens
play an important role in anti-tumor immunity, expanding evidence indicates that bona fide tumor-reactive T
cells comprise only a minor fraction of all TILs in many human tumors, indicating that most CD8+ TILs have
undefined specificity. Based on this long-standing question, we examined the hypothesis that a substantial
fraction of TILs may represent CD8+ "memory-phenotype" T cells (CD8-MP cells), a unique population of cells
of unknown antigen specificity that comprise 5-10% of CD8+ T cells in unprimed mice, exhibit common
hallmarks of prior antigen experience, and have the capacity to rapidly expand and produce IFN-γ during an
immune response. In preliminary work, we found that CD8-MP cells make substantial contributions to the
immune infiltrate of oncogene-driven prostate tumors, and express high densities of the PD-1 inhibitory
receptor. Given these unique insights, we embarked on parallel studies aimed at further elucidating the
fundamental biology of CD8-MP cells, using a clonal approach to define the developmental trajectories of
these cells. Our new data reveal that the differentiation of many CD8-MP clones is triggered by recognition of
self-ligands in the thymus via a reproducible, orchestrated process, challenging current thought suggesting that
CD8-MP cells differentiate in the periphery in response to homeostatic signals. In Aim 1, we will define the
function of CD8-MP cells in anti-tumor immunity, testing the hypothesis that self-ligand recognition drives the
early entry of CD8-MP cells into developing tumors, and that CD8-MP cells enhance anti-tumor immunity by
catalyzing broader immune cell infiltration. In addition, we will identify novel markers that can be used to
identify intratumoral CD8-MP cells, thereby enabling the broader study of CD8-MP cells in murine cancer
models and human cancer patients. In Aim 2, we will elucidate the molecular and cellular mechanisms that
direct CD8-MP differentiation, testing the hypothesis that CD8-MP differentiation is a two-step process
triggered by TCR-dependent recognition of self-ligands presented by classical dendritic cells in the thymus. We
will also utilize a unique T cell antigen discovery assay to identify natural self-peptides recognized by CD8-MP
cells, thereby opening new areas of inquiry that were previously inaccessible. Ultimately, defining the function
of intratumoral CD8-MP cells and the blueprints of CD8-MP differentiation in mice is expected to open new
avenues for the study and manipulation of these cells in humans.
摘要
虽然大量证据表明,CD 8 + TIL与突变或非突变的肿瘤抗原反应,
在抗肿瘤免疫中起重要作用,越来越多的证据表明真正的肿瘤反应性T细胞
在许多人类肿瘤中,CD 8+细胞仅占所有TIL的一小部分,这表明大多数CD 8 + TIL具有
未定义的特异性。基于这个长期存在的问题,我们研究了一个假设,
TIL的一部分可以代表CD 8+“记忆表型”T细胞(CD 8-MP细胞),一种独特的细胞群
在未致敏小鼠中包含5-10%的CD 8 + T细胞的未知抗原特异性,表现出常见的
具有先前抗原经验的标志,并且具有在免疫过程中快速扩增和产生IFN-γ的能力。
免疫反应在初步工作中,我们发现CD 8-MP细胞对肿瘤的发生有重要贡献。
免疫浸润癌基因驱动的前列腺肿瘤,并表达高密度的PD-1抑制
受体的鉴于这些独特的见解,我们开始了平行研究,旨在进一步阐明
CD 8-MP细胞的基础生物学,使用克隆方法来定义CD 8-MP细胞的发育轨迹。
这些细胞。我们的新数据表明,许多CD 8-MP克隆的分化是由识别CD 8-MP启动的。
胸腺中的自我配体通过一个可重复的,精心策划的过程,挑战目前的想法表明,
CD 8-MP细胞响应于稳态信号在外周中分化。在目标1中,我们将定义
CD 8-MP细胞在抗肿瘤免疫中的功能,检验自身配体识别驱动免疫的假设。
CD 8-MP细胞早期进入发展中的肿瘤,并且CD 8-MP细胞通过以下方式增强抗肿瘤免疫力:
催化更广泛的免疫细胞浸润。此外,我们将确定新的标记,可用于
鉴定肿瘤内的CD 8-MP细胞,从而能够更广泛地研究小鼠癌症中的CD 8-MP细胞
模型和人类癌症患者。在目标2中,我们将阐明分子和细胞机制,
直接CD 8-MP分化,检验CD 8-MP分化为两步过程的假设
由胸腺中经典树突状细胞呈递的自身配体的TCR依赖性识别触发。我们
还将利用独特的T细胞抗原发现测定来鉴定由CD 8-MP识别的天然自身肽
细胞,从而开辟了新的调查领域,以前无法进入。最终,定义函数
肿瘤内CD 8-MP细胞和小鼠中CD 8-MP分化的蓝图有望开辟新的
研究和操纵人类这些细胞的途径。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Peter Aidan Savage其他文献
Peter Aidan Savage的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Peter Aidan Savage', 18)}}的其他基金
Specificity of regulatory T cell suppression during infection
感染过程中调节性 T 细胞抑制的特异性
- 批准号:
10397705 - 财政年份:2021
- 资助金额:
$ 40.5万 - 项目类别:
Specificity of regulatory T cell suppression during infection
感染过程中调节性 T 细胞抑制的特异性
- 批准号:
10617672 - 财政年份:2021
- 资助金额:
$ 40.5万 - 项目类别:
Differentiation and function of intratumoral memory-phenotype CD8+ T cells
瘤内记忆表型 CD8 T 细胞的分化和功能
- 批准号:
10621183 - 财政年份:2020
- 资助金额:
$ 40.5万 - 项目类别:
Differentiation and function of intratumoral memory-phenotype CD8+ T cells
瘤内记忆表型 CD8 T 细胞的分化和功能
- 批准号:
10197020 - 财政年份:2020
- 资助金额:
$ 40.5万 - 项目类别:
Function of Aire-dependent regulatory T cells in immune tolerance
艾尔依赖性调节性 T 细胞在免疫耐受中的功能
- 批准号:
8886376 - 财政年份:2015
- 资助金额:
$ 40.5万 - 项目类别:
Identification of a prostate antigen recognized by endogenous regulatory T cells
内源性调节性 T 细胞识别的前列腺抗原的鉴定
- 批准号:
8750066 - 财政年份:2014
- 资助金额:
$ 40.5万 - 项目类别:
Function of Aire-dependent regulatory T cells in immune tolerance
艾尔依赖性调节性 T 细胞在免疫耐受中的功能
- 批准号:
8891580 - 财政年份:2014
- 资助金额:
$ 40.5万 - 项目类别:
Development and specificity of endogeneous tumor-infiltrating regulatory T cells
内源性肿瘤浸润调节性 T 细胞的发育和特异性
- 批准号:
8889208 - 财政年份:2011
- 资助金额:
$ 40.5万 - 项目类别:
Development and specificity of endogeneous tumor-infiltrating regulatory T cells
内源性肿瘤浸润调节性 T 细胞的发育和特异性
- 批准号:
8519972 - 财政年份:2011
- 资助金额:
$ 40.5万 - 项目类别:
Development and specificity of endogeneous tumor-infiltrating regulatory T cells
内源性肿瘤浸润调节性 T 细胞的发育和特异性
- 批准号:
8708779 - 财政年份:2011
- 资助金额:
$ 40.5万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 40.5万 - 项目类别:
Research Grant
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 40.5万 - 项目类别:
Operating Grants
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 40.5万 - 项目类别:
Small Business Research Initiative
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 40.5万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 40.5万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 40.5万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 40.5万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 40.5万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 40.5万 - 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 40.5万 - 项目类别: